As of Thursday close, Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) stock was up $0.08, moving up 3.64 percent to $2.28. The average number of shares traded per day over the past five days has been 5,645,220 shares. 4 times new highs have been achieved over the past 5 days, with a $0.20 gain in that time frame. In the last twenty days, the average volume was 5,719,655, while in the previous 50 days, it was 6,361,734.
Since last month, INO stock rose 10.68%. Shares of the company fell to $1.82 on 07/19/22, the lowest level in the past month. A 52-week high of $9.96 was reached on 01/04/22 after having rallying from a 52-week low of $1.38. Since the beginning of this year, INO’s stock price has dropped by -54.31% or -$2.71, and marked a new high 2 times. However, the stock has declined by -77.11% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Inovio Pharmaceuticals Inc. (INO) last reported insider trading activity 16 days ago on Jul 20. BENITO SIMON X, the Director of the company, disposed of 2,000 shares for $2.25 on Jul 20. It resulted in a $4,500 divestment by the insider. Weiner David B. sold 9,000 shares at an average price of $1.95 on May 16. The insider now owns 892,625 shares following the transaction. On May 16, Director Zoth Lota S. sold 3,600 shares at $1.98 apiece. The transaction was valued at $7,128.
The stock’s beta is 0.91. Besides these, the trailing price-to-sales (P/S) ratio of 351.13, the price-to-book (PB) ratio of 1.41.
The latest dividend of $0.0690 per share was paid out, remained unchanged from last year’s $0.0690.
In the three months ended March 30, Inovio Pharmaceuticals Inc.’s quick ratio stood at 6.70, while its current ratio was 6.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.05, and the total debt-to-equity ratio was 0.05. Based on annual data, INO earned $302.99 million in gross profit and brought in $1.77 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -72.60%. Return on equity (ROE) for the past 12 months was -76.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. INO’s revenue fell -31.03% to $1.74 million during the quarter, while net income inched up to $0.87 million. While analysts expected Inovio Pharmaceuticals Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.36 per share, beating the consensus estimate by -5.90%. During the quarter, the company generated -$70.23 million in EBITDA. The liabilities of Inovio Pharmaceuticals Inc. were 90.43 million at the end of its most recent quarter ended March 30, and its total debt was $33.65 million. The value of shareholders’ equity is $229.04 million.
This quick technical analysis looks at Inovio Pharmaceuticals Inc.’s (INO) price momentum. With a historical volatility rate of 66.68%, the RSI 9-day stood at 63.10% on 04 August.
With respect to its five-day moving average, the current Inovio Pharmaceuticals Inc. price is up by +9.62% percent or $0.20. At present, INO shares trade +8.57% above its 20-day simple moving average and -29.19% percent below its 100-day simple moving average. However, the stock is currently trading approximately +18.75% above its SMA50 and -67.52% below its SMA200.
Stochastic coefficient K was 62.93% and Stochastic coefficient D was 44.54%, while ATR was 0.18. Given the Stochastic reading of 80.17% for the 14-day period, the RSI (14) reading has been calculated as 59.14%. As of today, the MACD Oscillator reading stands at 0.10, while the 14-day reading stands at 0.12.
Inovio Pharmaceuticals Inc. (INO) has been rated Hold by analysts. According to 0 brokerage firms, INO is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Inovio Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $3.50, the current consensus forecast for the stock is $2.00 – $8.00. Based on these forecasts, analysts predict Inovio Pharmaceuticals Inc. (INO) will achieve an average price target of $4.25.